Bharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose six months after second dose.source https://timesofindia.indiatimes.com/india/covid-19-governments-expert-panel-allows-clinical-trials-for-third-dose-of-covaxin/articleshow/81869259.cms
Comments
Post a Comment